Edelson Lechtzin LLP Initiates Investigation into Arcturus Therapeutics for Potential Securities Violations

Investigation of Arcturus Therapeutics Holdings Inc.

Edelson Lechtzin LLP, a national class action law firm, has announced its investigation concerning Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) regarding potential violations of federal securities laws. This stems from allegations that the company provided misleading information regarding its business operations, which has led to significant stock price fluctuations and investor losses.

Background of Arcturus Therapeutics

Founded with the vision of innovating therapies and vaccines, Arcturus Therapeutics specializes in the development of mRNA-based solutions, particularly aimed at treating various diseases. The firm focuses on leveraging advanced technologies to create life-saving treatments and has made strides in the field of genetic medicine.

However, recent events have cast a shadow over its operations. On October 22, 2025, the company disclosed the results of a Phase 2 clinical trial for its inhaled mRNA therapy ARCT-032, targeting cystic fibrosis. Unfortunately for investors, the trial results showed no significant improvement in lung function, a critical metric for the treatment's efficacy. This announcement triggered a dramatic 50.17% decline in the company's stock price, closing at $11.54 per share.

The Allegations

Edelson Lechtzin LLP's investigation is focused on whether Arcturus Therapeutics knowingly provided misleading information that could have influenced investment decisions. Allegations suggest that the company may have misrepresented the viability and potential of its therapies, contributing to substantial financial losses for investors. The firm is actively seeking information from individuals who may have non-public insights into the situation or have suffered losses as a result of these developments.

How to Get Involved

Investors who feel they have been affected by the decline in Arcturus' stock value are encouraged to contact Edelson Lechtzin LLP for more information. Those interested can reach out by calling Eric Lechtzin at 844-563-5550 or via email at [email protected]. This opportunity allows investors to potentially take part in the unfolding justice process, particularly if they hold valuable information that could clarify the circumstances surrounding this case.

About Edelson Lechtzin LLP

Operating from offices located in Pennsylvania and California, Edelson Lechtzin LLP has a robust history of tackling cases involving securities fraud, antitrust law violations, and consumer protection, among other areas. The firm's commitment to safeguarding investors' rights and holding corporations accountable underscores their investigation into Arcturus Therapeutics. Their experience in class action lawsuits and securities litigation positions them well to navigate this complex matter.

Investors considering their options in light of the recent trial results and stock drop should act promptly, as timelines for potential recovery may be limited. While Edelson Lechtzin LLP stresses the importance of individual choices regarding legal representation, they stand ready to assist any affected parties in understanding their rights and potential courses of action.

Conclusion

As the investigation unfolds, the focus remains on understanding the inaccurate disclosures made by Arcturus Therapeutics and how they may have misled investors. This case illustrates the importance of transparency and accountability in the pharmaceutical sector, especially when it comes to life-saving innovations. Further updates are expected as more information comes to light, and investors need to remain vigilant in their pursuit of justice in the face of corporate misrepresentation.